Luye Pharma has issued a notice convening its Annual General Meeting (AGM) for 26 June 2026 at 15:00 in Yantai, Shandong Province, PRC. Key agenda items include:

1. Financial Statements • Shareholders will be asked to receive and adopt the audited consolidated financial statements and the directors’ and auditor’s reports for the year ended 31 December 2025.

2. Board Composition • Re-election of five directors: – Non-executive: Song Rui Lin. – Independent non-executive: Leung Man Kit, Zhang Hua Qiao and Choy Sze Chung Jojo—each having served the board for more than nine years. • The board will be authorised to set directors’ remuneration.

3. Auditor • Ernst & Young is nominated for re-appointment as external auditor until the next AGM, with the board authorised to determine its remuneration for the 2026 financial year.

4. Capital Mandates • General issuance mandate: authority to allot, issue, sell or transfer new or treasury shares up to 20% of issued share capital (excluding any treasury shares) as at the date of the AGM. • Share repurchase mandate: authority to buy back up to 10% of issued shares (excluding any treasury shares). • Extension mandate: the volume of shares repurchased under the buyback authority can be added to the 20% issuance limit.

5. Administrative Details • Share register closure: 23–26 June 2026 (both dates inclusive). • Record date for AGM attendance and voting: 26 June 2026. • Proxy forms must be lodged with Computershare Hong Kong Investor Services no later than 48 hours before the meeting.

The notice states that the board currently has no immediate plans to issue new shares and will exercise the repurchase mandate when deemed beneficial to shareholders.